Market Overview

Theravance Confirms Favorable Ruling from FDA Panel on VIBATIV

Related THRX
Short-Sellers Betting Against These Biotechs
Morning Market Losers
Healthcare Dividend Dogs: 3% To 10% Yields From Top 10 As Of July 29 (Seeking Alpha)

Theravance Inc. (NASDAQ: THRX) today announced a favorable outcome of the Anti-Infective Drugs Advisory Committee (AIDAC) of the U.S. FDA meeting on VIBATIV(R) (telavancin) for the treatment of nosocomial pneumonia (NP) due to susceptible isolates of Gram-positive microorganisms.

Posted-In: News FDA


Related Articles (THRX)

Get Benzinga's Newsletters